Tramadol for Labour Analgesia in Low Risk Primiparous Women
1 other identifier
interventional
100
1 country
1
Brief Summary
Tramadol is a centrally acting synthetic analgesic used to treat moderate to moderately severe pain. It has been previously evaluated as a method to reduce pain during labour, but there is always some fear related to its effects (neonatal respiratory depression). The purpose of our study was to evaluate the efficacy of subcutaneous tramadol in regards to pain during labour, duration of labour and neonatal outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_3
Started Oct 2012
Shorter than P25 for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2013
CompletedFirst Submitted
Initial submission to the registry
June 26, 2013
CompletedFirst Posted
Study publicly available on registry
July 1, 2013
CompletedJuly 9, 2013
July 1, 2013
7 months
June 26, 2013
July 7, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Pain during labour
Pain during labour was evaluated using the Visual Analogue Scale during the first six hours after the application of the drug (tramadol or placebo).
6 hours
Secondary Outcomes (4)
Duration of labour
12 hours
Neonatal outcomes
48 hours
Side effects
48 hours
Requirements of oxytocin
12 hours
Study Arms (2)
Tramadol
EXPERIMENTAL100 mg of tramadol SC (single dose) = 2 mL
Placebo
PLACEBO COMPARATOR2 mL of a sterile solution SC
Interventions
Eligibility Criteria
You may qualify if:
- Gestational age between 37 and 40 6/7 weeks
- Primiparous patient
- Singleton
- to 5 cms of dilation
- Intact membranes or spontaneous rupture of membranes less than 2 hours
- Fetus in a vertex presentation
- Gynecoid pelvis by clinical examination
You may not qualify if:
- Multiparous
- Multiple pregnancies
- Any pathology
- Induction of labour with prostaglandins
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Saint Thomas Maternity Hospital
Panama City, 1439 zona 9A, Panama
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Osvaldo Reyes, MD
Saint Thomas Maternity Hospital
- PRINCIPAL INVESTIGATOR
Riggie Castillo, MD
Saint Thomas Maternity Hospital
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Coordinator of Research
Study Record Dates
First Submitted
June 26, 2013
First Posted
July 1, 2013
Study Start
October 1, 2012
Primary Completion
May 1, 2013
Study Completion
June 1, 2013
Last Updated
July 9, 2013
Record last verified: 2013-07